Aditxt, Inc. Logo

Aditxt, Inc.

Acquires and develops biotech for autoimmunity, cancer detection, and neuro diagnostics.

ADTX | NDAQ

Overview

Corporate Details

ISIN(s):
US0070251097
LEI:
Country:
United States of America
Address:
737 N. FIFTH STREET, SUITE 200, 23219 RICHMOND
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Aditxt, Inc. is a biotechnology innovation company focused on discovering, developing, and deploying technologies to address significant health challenges. The company's business model centers on acquiring innovative and scalable life sciences companies and leveraging its business acceleration platform to drive growth and market penetration. Aditxt's portfolio includes programs targeting autoimmunity (Adimune), early cancer detection (Pearsanta), and neurological diagnostics (Adivue), with planned acquisitions in areas like reproductive health. The company aims to monetize these assets through strategic options such as mergers, sales, licenses, or IPOs to foster long-term growth.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aditxt, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aditxt, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aditxt, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France ALNFL
NGS Group Logo
Nordic staffing & recruitment for healthcare, education, and social services sectors.
Sweden NGS
Nihon M&A Center Holdings Inc. Logo
M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.
Japan 2127
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America OKYO

Talk to a Data Expert

Have a question? We'll get back to you promptly.